Lupkynis, Ikervis, Verkazia (voclosporin) is a protein pharmaceutical. Voclosporin was first approved as Lupkynis on 2015-03-19. It is used to treat lupus nephritis in the USA. It has been approved in Europe to treat conjunctivitis, corneal diseases, and keratitis. The pharmaceutical is active against peptidyl-prolyl cis-trans isomerase A. Lupkynis's patent is valid until 2037-12-07 (FDA).
|Trade Name||Ikervis, Verkazia|
|Indication||conjunctivitis, corneal diseases, keratitis, lupus nephritis|
|Drug Class||Cyclosporine derivatives|